HOME>News Release

News Release

  • Mitsubishi Tanabe Pharma
  • Former Mitsubishi Pharma
  • RSS
  • About RSS



November 7
Basic Agreement on the Establishment of a Joint VenturePDF
November 1
Announcement of FY2016 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
November 1
Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritisPDF
October 25
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017PDF
October 5
Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―PDF
October 4
Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine TabletsPDF
September 6
Application for partial change in administration/dosage for Crohn's disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
August 30
FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALSPDF
August 26
Valixa Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patientsPDF
August 23
Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets -PDF
August 2
Announcement of FY2016 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
June 22
Regarding Nomination Committee and Compensation CommitteePDF
June 20
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United StatesPDF
June 6
Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology FundPDF
May 13
Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in PsoriasisPDF
May 13
Corrections with respect to “Summary of Financial Results for year ended March 31, 2016” (Japan GAAP) (Consolidated)PDF
May 11
Announcement of Financial Results for FY2015
⇒R&D Pipeline "State of New Product Development"
May 11
Notice of Dividend of Retained EarningsPDF
April 27
Change of Representative Director, Director and Corporate AuditorPDF
April 4
MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in SingaporePDF
March 29
Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound LibrariesPDF
March 22
Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based ApplicationPDF
March 10
Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi subcutaneous injection 50 mg syringe (generic name: golimumab)PDF
February 23
Mitsubishi Tanabe Pharma Enhances Operations in the United StatesPDF
February 3
Announcement of FY2015 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 3
Notice Regarding Results of Early Retirement ProgramPDF

News Release

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide